Evidence map›Paper›PMID 29109685›Full record

ArticleFrontiers in pharmacology2017

Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB

Eva Martínez-Pinilla, Katia Varani, Irene Reyes-Resina, Edgar Angelats, Fabrizio Vincenzi, Carlos Ferreiro-Vera, Julen Oyarzabal, Enric I Canela, José L Lanciego, Xavier Nadal and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 193 citations in OpenAlex.

  1. Trial
  2. (+)-Trans-Cannabidiol Is an Agonist at Human CBPharmacology research & perspectives · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Cannabinoid CBACS pharmacology & translational science · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Research and Clinical Practice Involving the Use ofPharmaceuticals (Basel, Switzerland) · 2024
    Review
  20. Review

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Eva Martínez-PinillaInstituto de Neurociencias del Principado de Asturias, Departamento de Morfología y Biología Celular, Facultad de Medicina, Universidad de Oviedo, Asturias, Spain.
Katia VaraniPharmacology Institute, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Irene Reyes-ResinaMolecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biomedicine, University of Barcelona, Barcelona, Spain.
Edgar AngelatsMolecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biomedicine, University of Barcelona, Barcelona, Spain.
Fabrizio VincenziPharmacology Institute, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Carlos Ferreiro-VeraPhytoplant Research S.L., Córdoba, Spain.
Julen OyarzabalSmall Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
Enric I CanelaMolecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biomedicine, University of Barcelona, Barcelona, Spain.
José L LanciegoNeuroscience Department, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
Xavier NadalPhytoplant Research S.L., Córdoba, Spain.
Gemma NavarroMolecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biomedicine, University of Barcelona, Barcelona, Spain.
Pier Andrea BoreaPharmacology Institute, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Rafael FrancoMolecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biomedicine, University of Barcelona, Barcelona, Spain.
University of Ferrara · ITInstituto de Salud Carlos III · ESUniversidad de Navarra · ESUniversitat de Barcelona · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESInstituto de Investigación Sanitaria del Principado de Asturias · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanism of action of cannabidiol (CBD), the main non-psychotropic component of

Indexed as

allosterismendocannabinoidG-protein-coupled receptorirreversiblephytocannabinoidsSR144528TR-FRET

Identifiers

PMID29109685
PMCPMC5660261
OpenAlexW2765293449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.